Our Services

Pancreatic Cancer

Pancreatic cancer develops in the pancreatic ductal, acinar, and islet cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal (PDA) origin. Pancreatic cancer accounts for about 3% of all cancers in the United States. Risk factors that can be changed include tobacco use, obesity, and workplace exposure to certain chemicals.

Chemotherapy Plus Anti-hyaluronan Factor for Pancreatic Cancer Clinical Trial

  • Stage IV
  • All patients receive nab-Paclitaxel + Gemcitabine
  • Patients are randomized in a 2:1 ratio to receive chemotherapy + PEGylated Recombinant Human Hyaluronidase (PEGPH20) vs. chemotherapy + placebo
  • Patients must test Hyaluronan(HA)-High
  • Study website: http://halo301.com/
  • Main study doctor (Principal Investigator): Ian Anderson, MD
  • For more information, please contact the research department at 707-521-3830 or Kimberly.Young@stjoe.org